Gen Digital Inc. (GEN) Stock News

GENFIT, a biopharmaceutical company focused on rare liver diseases, has been admitted to the Euronext Paris CAC Mid 60 and SBF 120 indices effective September 18, 2026. The inclusion reflects the company's increased market capitalization, liquidity, and visibility, and is expected to enhance its profile among institutional investors.

GENFIT, a biopharmaceutical company focused on rare liver diseases, has been included in the Euronext Paris indices CAC Mid 60 and SBF 120, effective September 18, 2026. The inclusion reflects the company's increased market capitalization, liquidity, and visibility, and is expected to enhance its reputation among institutional investors. The company continues to develop therapeutic and diagnostic solutions, including the FDA-approved Iqirvo® for primary biliary cholangitis.

Hagens Berman has filed a securities fraud class action lawsuit against HDFC Bank Limited and its executives, alleging the bank concealed a scheme involving approximately Rs 45 crore ($4.7 million USD) in disguised payments to induce state deposits while providing above-market interest rates. The fraudulent practices allegedly violated RBI regulations and the bank's internal policies, resulting in overstated financials. The scheme surfaced following the resignation of the Chairman in March 2026 and an investigative report in May 2026, causing HDFC's stock to decline sharply. The class period covers July 17, 2023 to May 26, 2026, with a lead plaintiff deadline of October 13, 2026.

A comparison of Gen Digital (GEN) and Zeta Global Holdings (ZETA) as value investment opportunities. Gen Digital emerges as the superior value option with a Zacks Rank of #2 (Buy) versus ZETA's #3 (Hold), a lower forward P/E ratio of 10.65 compared to ZETA's 31.67, and a stronger Value grade of B versus ZETA's D grade.

Law firm Kirby McInerney LLP is investigating Myriad Genetics for potential securities fraud following the company's July 30, 2026 earnings report. Myriad reported an 11% year-over-year revenue decline to $190.7 million, reduced full-year guidance, and an $11 million revenue adjustment. Hereditary cancer testing revenue fell 13% despite volume growth, attributed to lower reimbursement and unfavorable estimate changes. Management acknowledged delayed engagement with payers regarding authorization and denial issues. The stock declined 47% to $2.86 on July 31, 2026.

Amgen Inc. disclosed a material data breach in July 2026 involving unauthorized access to cloud environments hosted by third-party providers, resulting in the exfiltration of patient protected health information and proprietary company data. The national class action law firm Edelson Lechtzin LLP is investigating potential legal claims on behalf of affected individuals and offering free case evaluations.

A securities class action has been filed against Cogent Communications Holdings, Inc. (CCOI) alleging the company made misleading statements about its dividend sustainability and pledged share risks. CCOI stock declined over 80% and the dividend was cut by 98%, with lenders seizing and selling $82.5 million in pledged stock. Investors who purchased between February 29, 2024 and May 1, 2026 may be eligible to participate in the lawsuit, with a September 21, 2026 deadline for lead plaintiff applications.

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging the company made false statements about Fabric Genomics and overstated the durability of reimbursement rates. On May 4, 2026, GeneDx revealed a $57.5 million operational loss, lowered 2026 revenue guidance by $65 million, and took a $31.3 million write-down on Fabric Genomics. The stock price fell approximately 50% from $67.93 to $34.51 per share. Investors have until August 3, 2026 to apply as lead plaintiff.

Aimei Health Technology Co., Ltd. announced the termination of its Business Combination Agreement with United Hydrogen Group Inc. on July 7, 2026, due to failure to close the transaction by the outside date specified in the agreement. The company expressed confidence in identifying future transaction opportunities.

GENFIT announced positive Phase 1b results for GNS561, an investigational drug targeting autophagy, in combination with a MEK inhibitor for treating advanced KRAS-mutated cholangiocarcinoma. The study of 19 patients showed a favorable safety profile with no dose-limiting toxicities and early signs of antitumor activity, with approximately half achieving stable disease. Phase 2 initiation is planned for the second half of 2026.

GENFIT reported positive Phase 1b results for GNS561 combined with a MEK inhibitor in heavily pretreated cholangiocarcinoma patients with KRAS mutations. The drug demonstrated favorable safety and tolerability profiles with no dose-limiting toxicities, along with early signs of antitumor activity. Approximately half of the 19 patients achieved stable disease at Week 6, with one patient maintaining this status through Week 30. The company plans to extend Phase 1b with additional cohorts at higher doses and proceed to Phase 2 launch in H2 2026.

Rosen Law Firm is encouraging investors with losses exceeding $100,000 in Regencell Bioscience Holdings Limited, FS KKR Capital Corp., and Microsoft to join securities class action lawsuits. The firm has set a June 23, 2026 deadline for lead plaintiff claims. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities and regulatory risks.

Rosen Law Firm is reminding investors in Regencell Bioscience Holdings Limited (RGC) and AeroVironment, Inc. (AVAV) of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities, regulatory risks, and financial exposure during their respective class periods.

Excluding significant items, quarterly earnings per common share of $0.48 (1) Increased quarterly dividend 17.6 % to $ 0.10 per common share TORONTO , June 3, 2026 /CNW/ - Canaccord Genuity Group Inc. (Canaccord Genuity Group, the Company) (TSX: CF ) today announced its financial results for the fourth quarter and fiscal year ended March 31, 2026. "We delivered record revenue in fiscal 2026 and significantly improved profitability, reflecting stronger operating leverage and disciplined execution across the platform," said Dan Daviau, Chairman & CEO of Canaccord Genuity Group Inc. "Capital markets growth was led by higher investment banking and advisory activity, while wealth management continued to scale, supported by market appreciation, targeted investment and positive inflows. Our improved earnings profile and continued focus on disciplined capital allocation supported our decision to increase the dividend, while preserving the flexibility to invest in the areas of the business where we see the strongest opportunities to create long-term shareholder value." Fourth quarter and fiscal 2026 highlights (adjusted): (All dollar amounts are stated in thousands of Canadian dollars and on an adjusted basis excluding significant items ( 1 ) unless otherwise indicated) Fourth quarter revenue of $612.7 million, an increase of 33.2% over the same period in the prior fiscal year and the third highest quarterly revenue on record Fiscal 2026 revenue of $2.2 billion increased by 24.9% year over year Global wealth management operations earned record quarterly revenue of $306.7 million and record revenue of $1.1 billion for fiscal 2026, year-over-year improvements of 28.4% and 24.2%. Fourth quarter growth in the Australian wealth management operations reflects contributions from the acquisition of Wilsons Advisory Global capital markets revenue for the fourth quarter of $291.6 mi

Publicis Groupe held its annual shareholders' meeting on May 27, 2026, with an 80.78% quorum approving all 23 resolutions. The company approved a dividend increase of 4.17% to 3.75 euros per share and appointed new board members Benjamin Badinter and Jaime Teevan. CEO Arthur Sadoun highlighted strong 2025 performance with 5.6% organic growth and confirmed 2026 objectives despite uncertain macroeconomic conditions.

Metallium Limited presented its patented Flash Joule Heating (FJH) technology at the Canaccord Genuity Global Metals and Mining Conference, positioning it as a solution to reduce U.S. reliance on China for critical metals processing. The company, which recently received a Department of War grant for gallium and germanium recovery from e-waste, is pursuing a NASDAQ uplist expected later in 2026 and focusing on urban mining/recycling and mineral processing verticals.

TORONTO , May 20, 2026 /CNW/ - Canaccord Genuity Group Inc. (TSX: CF ) is scheduled to release its fourth quarter and fiscal 2026 financial results and supplementary financial information after Canadian markets close on Wednesday, June 3, 2026. The conference call is scheduled for Thursday, June 4, 2026, at 8:00 a.m. Eastern time. Investors and other stakeholders can access the earnings release and supplementary financial information at www.cgf.com/investor-relations/investor-resources/financial-reports/ QUARTERLY CONFERENCE CALL AND WEBCAST: Interested parties are invited to listen to Canaccord Genuity's fourth quarter and fiscal 2026 results conference call via live webcast or a toll-free number. The conference call may be accessed live ... Full story available on Benzinga.com

Nature's Miracle Holding Inc. has entered into a Memorandum of Understanding with DROMNI Intelligence Technology Ltd. to collaborate on developing and commercializing AI-enabled autonomous robotics solutions for the U.S. agriculture, energy, and data center markets. The partnership will focus on unmanned ground vehicle deployment, smart infrastructure automation, and pilot programs across greenhouse operations, logistics, energy infrastructure, and industrial automation.

Law firm Bragar Eagel & Squire is investigating Qiagen N.V. for potential securities law violations. The investigation was triggered after Qiagen's Q1 2026 results showed net sales declined 1% and QuantiFERON product sales fell 5%, contradicting the company's February guidance of 6-7% growth. The stock price dropped 11% following the announcement.